
Diageo, UP Fintech, and Regencell Bioscience are the three Chinese stocks to watch today, according to MarketBeat’s stock screener tool. “Chinese stocks” are equity securities issued by companies that are incorporated in China or derive a substantial portion of their revenue from Chinese operations, and they can include mainland A?shares, Hong Kong–listed H?shares, and foreign?listed depositary receipts (e.g., ADRs). Investors can buy them on mainland exchanges (Shanghai, Shenzhen), in Hong Kong, or on overseas markets, and should consider China?specific factors such as regulatory policy, currency exposure, market access rules, and corporate governance when assessing risk and return. These companies had the highest dollar trading volume of any Chinese stocks within the last several days.
Diageo (DEO)
Diageo plc, together with its subsidiaries, engages in the production, marketing, and sale of alcoholic beverages. The company offers scotch, gin, vodka, rum, raki, liqueur, wine, tequila, Chinese white spirits, cachaça, and brandy, as well as beer, including cider and flavored malt beverages. It also provides Chinese, Canadian, Irish, American, and Indian-Made Foreign Liquor whiskies, as well as flavored malt beverages, ready to drink, and non-alcoholic products.
UP Fintech (TIGR)
UP Fintech Holding Limited provides online brokerage services focusing on Chinese investors. The company has developed a brokerage platform, which allows investor to trade stocks, options, warrants, and other financial instruments that can be accessed through its APP and website. It offers brokerage and value-added services, including investor education, community engagement, and IR platform services.
Read Our Latest Research Report on TIGR
Regencell Bioscience (RGC)
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
Read Our Latest Research Report on RGC
Featured Stories
- MarketBeat’s Top Five Stocks to Own in November 2025
- Nebius Partners With Meta—AI Growth Could Send Stock to New Highs
- EVgo’s 37% Revenue Growth: Forget the Car, Buy the Gas Station
- ServiceNow’s AI Efficiency Push Has Analysts Targeting Big Gains
- Microsoft and IREN’s $9.7B AI Deal Could Spark MSFT Stock Rally
- Datavault AI’s 314% Upside: Huge Potential or Wall Street Mirage?
